Understanding the Burden of Menopausal Vasomotor Symptoms

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP

Key Takeaways

Up to 80% of women experience VMS during menopause, with symptoms lasting a median of 7.4 years.
VMS symptoms are often moderate to severe, impacting quality of life significantly.
Racial and ethnic disparities exist, with Black women experiencing more severe and prolonged VMS.
Tailored patient interactions and management strategies are essential to address these disparities effectively.

Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.

Now Viewing

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP: 9.Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP: 10.Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

Let’s begin by discussing the impact of VMS related to menopause and the large number of people affected. According to the SWAN[Study of Women’s Health Across the Nation] data, up to 80% of women experience these symptoms, with a median duration of 7.4 years. Additionally, most women describe the severity of their symptoms as moderate to severe. How does this compare to with the types of symptoms, severity, and duration that you’re seeing among the women in your practice?
There also appears to be racial and ethnic differences, with Black women experiencing a higher prevalence, duration, and severity of VMS than women of other races or ethnicities. How do these differences impact your interactions with your patients?

DISCLAIMER: It was incorrectly cited that data from the SKYLIGHT 3 clinical trial pointed to lowered efficacy of VEOZAH in Asian women. It was the Phase 3 MOONLIGHT 1 clinical trial based in East Asia that did not show a reduction in the frequency or severity of VMS versus placebo in postmenopausal women.